Evicita · Supplement evidence, graded and cited · Supplements · Lifestyle · Mechanisms · Lab tests · 中文

Urolithin A

Urolithin A (Mitopure) · also known as Urolithin A, UA, Mitopure, Pomegranate ellagic acid gut metabolite

Urolithin A is a metabolite that gut bacteria make from pomegranate ellagitannins. Human randomized trials have observed changes in some muscle and mitochondrial markers, but improvements in autophagic flux, muscle strength and mitochondrial respiratory efficiency have not been consistently confirmed.

Typical dose: Standard high-purity urolithin A, 500–1000 mg/day, taken in the morning
Absorption and forms: The crystalline form has very poor water solubility. High-purity micronized or lipid-based formulations are better absorbed orally, and bioavailability is also higher when taken on an empty stomach or with a little fat.

Clinical uses and human evidence

Muscle strength and mass

Mixed resultsGrade B · Moderate evidence
Studies (2)
  1. Dao 2026 · Front Nutr · Meta-analysis · n=236 — Effects of Urolithin A supplementation on muscle health outcomes in humans from randomized controlled trials
  2. Singh 2022 · Cell Rep Med · RCT · n=88 — Urolithin A improves muscle strength, exercise performance, and biomarkers of mitochondrial health in a randomized trial in middle-aged adults

Endurance performance

Mixed resultsGrade B · Moderate evidence
Studies (2)
  1. Dao 2026 · Front Nutr · Meta-analysis · n=236 — Effects of Urolithin A supplementation on muscle health outcomes in humans from randomized controlled trials
  2. Liu 2022 · JAMA Netw Open · RCT · n=66 — Effect of Urolithin A Supplementation on Muscle Endurance and Mitochondrial Health in Older Adults: A Randomized Clinical Trial

Mechanisms of action

Selective induction of mitophagy (PINK1-Parkin)

★★★★☆Mechanism evidence: grade APrimary target

Urolithin A can modulate markers of the PINK1/Parkin pathway in muscle. In one human randomized trial, phosphorylated Parkin rose in muscle biopsies from the 500 mg/day group, and the analysis was mainly a within-group before-and-after comparison. Autophagic flux and clinical effects remain undetermined.

References (1)
  1. Singh et al. 2022 · Human RCT: phosphorylated Parkin increased in muscle biopsies from the 500 mg/day group, with analysis mainly comparing before and after within groups

Inhibition of NF-κB / AP-1, the master switches of pro-inflammatory transcription

★★☆☆☆Mechanism evidence: grade CSecondary target

In a sleep-deprivation mouse model, urolithin A reduced NF-κB- and NLRP3-related signaling in the hippocampus. Changes in human inflammatory markers cannot by themselves prove NF-κB inhibition. The cGAS–STING and NLRP3 pathways are also not the same thing as NF-κB, and human evidence is still insufficient.

References (1)
  1. 2024 · Mouse study: urolithin A suppressed NF-κB/NLRP3-related signaling in the hippocampus in a sleep-deprivation model

Safety and drug interactions

Generally well tolerated at usual doses. Safety data in pregnancy and breastfeeding are not yet adequate, so consult a doctor.
Open in the interactive app ›